VERTEX PHARMA - Time to Book Profits
Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the current price the risk reward is well balanced. Positive read out of KALYDECO/VX-809 (CF potentiator/ CF corrector) combination in homozygous del508 mutation cystic fibrosis (CF) pts from PhIIb (data expected in mid-12) and PhIII trial, and other pipeline drugs can take the stock to new high, but failure along with disappointment in future sales of INCIVEK (HCV, telaprevir, L) could have major impact! Though we have positive expectations from KALYDECO/VX-809 in subpopulation, we expect the stock to remain volatile in the next one year due to CF related milestones, INCIVEK sales, and news from highly competitive HCV drugs pipeline…..For more detail, please read our report released on 11th June, 2012 on Vertex titled “Time to Book Profits….!”
COMPANIES MENTIONED
Vertex Pharma
Vertex Pharma
